CA2848711C - Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease - Google Patents

Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease Download PDF

Info

Publication number
CA2848711C
CA2848711C CA2848711A CA2848711A CA2848711C CA 2848711 C CA2848711 C CA 2848711C CA 2848711 A CA2848711 A CA 2848711A CA 2848711 A CA2848711 A CA 2848711A CA 2848711 C CA2848711 C CA 2848711C
Authority
CA
Canada
Prior art keywords
residues
rhamnogalacturonate
pharmaceutical composition
liver
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2848711A
Other languages
English (en)
French (fr)
Other versions
CA2848711A1 (en
Inventor
Peter G. Traber
Eliezer Zomer
Anatole A. Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Therapeutics Inc
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Publication of CA2848711A1 publication Critical patent/CA2848711A1/en
Application granted granted Critical
Publication of CA2848711C publication Critical patent/CA2848711C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2848711A 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease Active CA2848711C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535655P 2011-09-16 2011-09-16
US61/535,655 2011-09-16
US201261656288P 2012-06-06 2012-06-06
US61/656,288 2012-06-06
PCT/US2012/055360 WO2013040324A1 (en) 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CA2848711A1 CA2848711A1 (en) 2013-03-21
CA2848711C true CA2848711C (en) 2019-08-06

Family

ID=47883762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848711A Active CA2848711C (en) 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Country Status (12)

Country Link
US (2) US8658787B2 (enExample)
EP (1) EP2755480B1 (enExample)
JP (1) JP6185473B2 (enExample)
KR (1) KR101974675B1 (enExample)
CN (1) CN103945695B (enExample)
AU (1) AU2012308491B2 (enExample)
BR (1) BR112014006220A2 (enExample)
CA (1) CA2848711C (enExample)
ES (1) ES2869884T3 (enExample)
IL (1) IL231512B (enExample)
MX (1) MX360979B (enExample)
WO (2) WO2013040316A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
WO2014043708A1 (en) * 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
EP3046566B1 (en) * 2013-09-19 2020-12-02 The Research Foundation for The State University of New York Methods and materials for treating liver steatosis
WO2015138438A1 (en) * 2014-03-10 2015-09-17 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
EP3191110A4 (en) * 2014-08-18 2018-04-18 Pharmagenesis, Inc. Polygalacturonan rhamnogalacturonan1 (pgrg1) composition
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
AU2016226906B2 (en) * 2015-03-03 2021-06-10 KOHJIN Life Sciences Co., Ltd. Composition for improving or preventing nonalcoholic fatty liver
EP3273972A4 (en) 2015-03-27 2018-10-31 The Research Foundation for The State University of New York Methods and materials for reducing amyloid beta levels within a mammal
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
TWI881480B (zh) * 2015-06-30 2025-04-21 美商伊格集團國際股份有限公司 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
JP7086008B2 (ja) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN109475537A (zh) * 2016-06-03 2019-03-15 坎莫森特里克斯公司 治疗肝纤维化的方法
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
WO2018191752A1 (en) 2017-04-14 2018-10-18 Gelesis Llc Compositions and methods for treating or preventing gut permeability-related disorders
AU2018265571B2 (en) 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019010024A1 (en) * 2017-07-04 2019-01-10 The Regents Of The University Of California METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH INFLAMMATION OF DOOR SPACE OR PERIODAL INFLAMMATION
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
GB201804922D0 (en) * 2018-03-27 2018-05-09 Ucl Business Plc Traatment
EP3813883A1 (en) 2018-06-29 2021-05-05 Glykos Biomedical Oy Conjugates
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
AU2021273936A1 (en) * 2020-05-22 2022-12-08 Durect Corporation Treatment of non-alcoholic steatohepatitis (NASH)
EP4240413A4 (en) * 2020-11-06 2024-10-16 NDPD Pharma, Inc. POLYSACCHARIDES FOR USE IN THE TREATMENT OF SARS-COV-2 INFECTIONS

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011285A1 (de) 1990-04-06 1991-10-10 Steigerwald Arzneimittelwerk Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose
US6297229B1 (en) 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US6180139B1 (en) 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
WO2000062076A1 (en) * 1999-04-13 2000-10-19 Hsu Daniel K Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
AU777254B2 (en) 1999-04-20 2004-10-07 Board Of Trustees Of Southern Illinois University, The Methods of treating clinical diseases with isoflavones
CN1142272C (zh) 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
CN100558407C (zh) 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
KR20040019069A (ko) 2001-07-20 2004-03-04 인터뮨, 인크. 간섬유증의 치료 방법
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
EP1765874A1 (en) * 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
JP2008105945A (ja) 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
WO2007016390A1 (en) * 2005-07-28 2007-02-08 Children's Medical Center Corporation Matrix metalloproteinase inhibitors for treating fatty liver disease
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
TWI535435B (zh) * 2007-11-30 2016-06-01 美國加利福尼亞大學董事會 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
WO2009118343A1 (en) 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for determining the occurrence of a liver disease in a subject
US20110082119A1 (en) 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
ES2621838T3 (es) * 2008-11-18 2017-07-05 Universite D'angers Método in vitro no invasivo para la cuantificación de lesiones hepáticas
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
AU2012363033B2 (en) * 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases

Also Published As

Publication number Publication date
JP2014526513A (ja) 2014-10-06
US20130259870A1 (en) 2013-10-03
BR112014006220A2 (pt) 2017-04-11
EP2755480B1 (en) 2021-03-31
EP2755480A1 (en) 2014-07-23
EP2755480A4 (en) 2015-04-29
JP6185473B2 (ja) 2017-08-23
WO2013040316A1 (en) 2013-03-21
US20130171151A1 (en) 2013-07-04
US8658787B2 (en) 2014-02-25
KR20140107180A (ko) 2014-09-04
AU2012308491B2 (en) 2016-01-07
ES2869884T3 (es) 2021-10-26
CN103945695B (zh) 2018-04-17
MX360979B (es) 2018-11-22
AU2012308491A1 (en) 2014-04-03
CN103945695A (zh) 2014-07-23
KR101974675B1 (ko) 2019-05-02
IL231512B (en) 2019-02-28
IL231512A0 (en) 2014-04-30
MX2014003213A (es) 2015-05-15
WO2013040324A1 (en) 2013-03-21
CA2848711A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
AU2012308491B2 (en) Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
US20260053840A1 (en) Composition of novel carbohydrate drug for treatment of human diseases
JP6517141B2 (ja) 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170817

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240730